ESTRO/EANO recommendation on reirradiation of glioblastoma

被引:0
|
作者
Andratschke, Nicolaus [1 ]
Heusel, Astrid [1 ]
Albert, Nathalie L. [2 ]
Alongi, Filippo [3 ,4 ]
Baumert, Brigitta G. [5 ]
Belka, Claus [6 ]
Castellano, Antonella [7 ,8 ,9 ]
Dhermain, Frederic [10 ]
Erridge, Sara C. [11 ]
Grosu, Anca-L. [12 ]
Lagerwaard, Franciscus [13 ]
Lukacova, Slavka [14 ]
Rosenschold, Per Munck af [15 ,16 ]
Niyazi, Maximilian [17 ]
Nieder, Carsten [18 ,19 ]
Preusser, Matthias [20 ]
Smits, Marion [21 ]
Weber, Damien C. [1 ,22 ]
Weber, Wolfgang [23 ]
Weller, Michael [24 ,25 ,26 ]
Williamson, Aoife
Minniti, Giuseppe [27 ]
机构
[1] Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland
[2] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Nucl Med, Munich, Germany
[3] IRCCS Sacro Cuore Don Calabria Hosp, Adv Radiat Oncol Dept, Negrar Di Valpolicella, Italy
[4] Univ Brescia, Brescia, Italy
[5] Cantonal Hosp Graubunden, Inst Radiati Oncol, Chur, Switzerland
[6] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Univ Hosp, Munich, Germany
[7] Univ Vita Salute San Raffaele, IRCCS Osped San Raffaele, Neuroradiol Unit, Milan, Italy
[8] Univ Vita Salute San Raffaele, CERMAC, Milan, Italy
[9] IRCCS Osped San Raffaele, Milan, Italy
[10] Gustave Roussy Univ Hosp, Dept Radiotherapy, Villejuif, France
[11] Univ Edinburgh, Western Gen Hosp, Edinburgh Ctr Neurooncol, Edinburgh, Midlothian, Scotland
[12] Univ Med Ctr Freiburg, Dept Radiat Oncol, Freiburg, Germany
[13] Vrije Univ Amsterdam, Med Ctr, Dept Radiat Oncol, Amsterdam, Netherlands
[14] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark
[15] Skane Univ Hosp, Radiat Phys, Dept Hematol Oncol & Radiat Phys, Lund, Sweden
[16] Lund Univ, Med Radiat Phys, Lund, Sweden
[17] Univ Hosp Tubingen, Dept Radiat Oncol, Tubingen, Germany
[18] Nordland Hosp Trust, Dept Oncol & Palliat Med, Bodo, Norway
[19] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Clin Med, Tromso, Norway
[20] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria
[21] Univ Med Ctr Rotterdam, Dept Radiol & Nucl Med, Erasmus MC, Rotterdam, Netherlands
[22] Paul Scherrer Inst, Ctr Proton Therapy, Villigen, Switzerland
[23] Tech Univ Munich, Dept Nucl Med, Munich, Germany
[24] Univ Hosp, Dept Neurol, Zurich, Switzerland
[25] Univ Hosp, Brain Tumor Ctr, Zurich, Switzerland
[26] Univ Zurich, Zurich, Switzerland
[27] IRCCS Neuromed, Pozzilli, IS, Italy
关键词
Reirradiation; Glioblastoma; Guideline; Target definition; Dose; HIGH-GRADE GLIOMA; HYPOFRACTIONATED STEREOTACTIC REIRRADIATION; RECURRENT MALIGNANT GLIOMAS; GAMMA-KNIFE RADIOSURGERY; AMINO-ACID PET; SPINAL-CORD; RADIATION-THERAPY; PHASE-II; BEVACIZUMAB; EFFICACY;
D O I
10.1016/j.radonc.2024.110696
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Purpose: Although reirradiation of glioblastoma has a long history of clinical practice, guidance on how to perform it in the context of recent technological advances, modern imaging modalities or systemic therapy is scarce. This joint ESTRO/EANO guideline aims to collect the existing evidence to produce recommendations for safe reirradiation of glioblastoma. Methods: The basis of this ESTRO/EANO clinical practice guideline are nine key questions (KQ) which were formulated by a consortium of radiation-oncologists, radiologists, medical oncologists, neurooncologists, medical physicists and radiation therapists. A systematic review was conducted and the KQ were addressed based on this evidence and expert opinion to draft recommendations and statements which were then voted on in a modified DELPHI process. Results: The DELPHI consensus process resulted in 18 recommendations and nine statements of which all achieved group consensus. Thirteen (48%) were based on available prospective evidence and 14 (52%) on expert opinion. Level of evidence did not exceed "moderate", reflecting the scarcity of prospective randomized evidence for most aspects of reirradiation. Consensus recommendations and statements reflected aspects of patient se- lection, imaging for recurrence assessment, target volume delineation, treatment planning, combined modality treatment, and follow-up. Conclusions: Currently, based on the ESTRO/EANO consensus, reirradiation may be considered in selected pa- tients with glioblastoma. GTV definition is based on T1-weighted MR-sequences, while a GTV to CTV margin is not mandatory. A PTV margin of maximum 3 mm is recommended based on the individual mask system and IGRT procedures. A biological effective dose greater than 36 Gy in 2 Gy fractions is recommended. A careful assessment of prognostic factors on survival such as age, interval from initial radiation, large treatment volumes, poor KPS, and poor neurologic/neurocognitive status is essential for making a clinical recommendation.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Pattern of recurrence after fractionated stereotactic reirradiation in adult glioblastoma
    Margulies, Agathe
    Sahki, Nassim
    Rech, Fabien
    Vogin, Guillaume
    Blonski, Marie
    Peiffert, Didier
    Taillandier, Luc
    Lesanne, Gregory
    Demogeot, Nicolas
    RADIATION ONCOLOGY, 2025, 20 (01)
  • [22] Impact of Reirradiation Utilizing Fractionated Stereotactic Radiotherapy for Recurrent Glioblastoma
    Shields, Lisa B.
    O'Dell, Patrick
    Daniels, Michael W.
    Sevak, Parag R.
    Highfield, Hilary A.
    Sinicrope, Kaylyn D.
    Sun, David A.
    Spalding, Aaron C.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
  • [23] Proton Therapy Reirradiation in Difficult-to-Treat Recurrent Glioblastoma
    Amelio, D.
    Scartoni, D.
    Farace, P.
    Widesott, L.
    Lorentini, S.
    Vennarini, S.
    Fellin, F.
    Brugnara, S.
    Maines, F.
    Schwarz, M.
    Amichetti, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E63 - E64
  • [24] Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients
    Wolfgang Wick
    Andriy Krendyukov
    Klaus Junge
    Thomas Höger
    Harald Fricke
    Journal of Neuro-Oncology, 2019, 145 : 531 - 540
  • [25] Salvage reirradiation for recurrent glioblastoma: a retrospective case series analysis
    Calduch, Anna Lucas
    Garau, Miquel Macia
    Freixa, Salvador Villa
    Exposito, Nagore Garcia
    Farre, Ignasi Modolell
    Torro, Carles Majos
    Escoda, Albert Pons
    Barroso, Carlos Mesia
    Quintela, Noelia Vilarino
    Gomez, Aleix Rossello
    Ahicart, Gerard Plans
    Garcia, Maria Martinez
    Gomez, Anna Esteve
    Escuer, Jordi Bruna
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [26] PROGNOSTIC FACTORS AND OUTCOMES OF PATIENTS TREATED WITH REIRRADIATION FOR RECURRENT GLIOBLASTOMA
    Beadle, Beth
    Mahajan, Anita
    Chang, Eric L.
    Woo, Shiao Y.
    Sulman, Erik P.
    McAleer, Mary F.
    Maor, Moshe
    Suki, Dima
    Gilbert, Mark R.
    Pelloski, Christopher E.
    NEURO-ONCOLOGY, 2009, 11 (05) : 661 - 661
  • [27] Reirradiation for glioblastoma with temozolomide: Delicate balance between effectiveness and toxicity
    Gupta, D.
    Kataria, T.
    Bisht, S. S.
    Goyal, S.
    Basu, T.
    Abhishek, A.
    Narang, K.
    Banerjee, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma
    G. Minniti
    V. Armosini
    M. Salvati
    G. Lanzetta
    P. Caporello
    M. Mei
    M. F. Osti
    R. Enrici Maurizi
    Journal of Neuro-Oncology, 2011, 103 : 683 - 691
  • [29] Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients
    Wick, Wolfgang
    Krendyukov, Andriy
    Junge, Klaus
    Hoeger, Thomas
    Fricke, Harald
    JOURNAL OF NEURO-ONCOLOGY, 2019, 145 (03) : 531 - 540
  • [30] Exploiting Deep Learning to Enhance Tumour-conformed Delineation and Reduced Isotropic Margin in Radiotherapy: Updated ESTRO-EANO Guidelines
    Hannisdal, M. H.
    Goplen, D.
    Lundervold, A.
    Chekenya, M.
    CLINICAL ONCOLOGY, 2023, 35 (10) : E636 - E638